-
DeepSeek: On Data, Hype, and True Cost

DeepSeek has captivated the world’s attention in the last few weeks. If, by chance, you’ve been living under a rock, the value proposition of the model is: The reception has been swift and intense. Nvidia’s stock tanked 17%, or $600 billion (a.k.a. 100K DeepSeeks) on fears of decreased chip demand. Marc Andreessen, the famed investor,…
-
Challenges of AI Safety: LLM Guardrails and Model Alignment

Recently, Sam Altman posted a picture of a strawberry plant and the X-verse went ablaze. Was he teasing the rumored new model? Was it a meaningless ode to summer? A poke at the fact that LLMs can’t count the R’s in S-T-R-A-W-B-E-R-R-Y? Time will tell. One thing is certain: LLMs will continue to get faster,…
-
AlphaFold 3: Revolutionizing Drug Discovery with ML Protein Prediction

Or, Sometimes Sequels Really are Better One source of flak ML often gets goes something like this: “Ok, ok, these magical chatbots and robo-Picassos are cool and all, but how can ML actually help the world?” Fair enough. One area in desperate need of a shakeup is drug discovery. This field is notoriously slow, often…
